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Abstract
Breast and prostate cancers are common types of cancers with various strategies, such as chemotherapy and
radiotherapy, for their therapy. Since these methods have undesired side effects and poor target affinity,
neoteric strategies—known as aptamer-based smart drug delivery systems (SDDSs)—have been developed in
recent years to overcome the obstacles of current treatment, and investigated for a clinical trial. The high
affinity and versatility of aptamers for binding to the corresponding targets make them highly noticeable agents
in the drug delivery domains. In addition to their exceptional benefits, aptamers are able to overcome tumor
resistance because of their high selectivity and low toxicity. Furthermore, aptamers can conjugate with various
drugs, nanoparticles and antibodies and effectively deliver them to the specific breast and prostate cells. This
review highlights the current researches in aptamer-conjugate developments for targeting breast and prostate
cancers, with the special focus on the nanoparticle-aptamer bioconjugates, systematic evolution of ligands by
exponential enrichment (SELEX) system and SDDS, especially cutting-edge articles from 2008 to present. Finally,
the future prospects and challenges are described.

Graphical abstract
Breast and prostate cancers' mortality as the most important types of cancers have taken a heavy toll on women
and men, respectively; hence there is a growing need for assessing diagnosis and treatment. Threfore, in this
review, the recent advances in aptamer-bioconjugates treatments of breast and prostate cancers are highlited.
Also, nanoparticle-aptamer bioconjugates, SELEX system and SDDS as the main approaches for these treatments
are critically reviewed.
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1. Introduction
Breast and prostate cancers are the two most leading invasive human cancers, in terms of incidence, worldwide.
For decades, therapy methods were confined to tumor cells or tissue morphologies instead of identifying the
specifically targeted sites. Chemotherapy and radiation are primary therapies utilized for treating these cancers,
but their major drawbacks forced researchers to discover neoteric treatment approaches [1]. Additionally, drugs
that are commonly used for cancer treatment have some serious disadvantages, such as lack of solubility,
bioavailability and fast blood clearance [2]. Therefore, concerns about diagnosis and therapeutic factors [3,4],
along with recent developments in the pathophysiology of these cancers, open a new avenue leading to the
novel treatment strategies [5].
Smart drug delivery systems (SDDS) have emerged as a cure-all for many useful chemotherapy drugs suffering
from high toxicity. These systems are based on nanocarriers—such as dendrimers, liposomes, micelles and gold
nanoparticles—in order to tackle the nonspecific and uncontrollable release [6] due to their low toxicity, half-life
enhancement and cytotoxic protection from degradation [7]. These systems have benefits in comparison with
traditional cancer therapies, such as reducing drug dosage and side effects [8]. Besides, targeted drug delivery
systems exhibit dramatic results in identifying the malignant tumor, like improving the efficacy of selective
distribution and controllable drug release at tumor locations [9]. Meanwhile, using nanocarriers-aptamers that
are able to bind with various biological targets (i.e. peptides, antibodies and nucleic acids) are in the spotlight
nowadays due to the shortage of immunogenicity and the higher proportion of target accumulation [10].
Aptamers are simple, small, single-stranded deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) that bind to
target molecules with their high affinity and specificity by folding into a three-dimensional conformation similar
to antibodies [11,12]. Aptamers can typically bind to various molecules, such as overexpressed receptors,
through an in vitro iterative selection method termed SELEX (Systematic Evolution of Ligands by Exponential
Enrichment) for diagnostic and therapeutic purposes [13]. In comparison with antibodies, aptamers are more
beneficial, less toxic and easier to modify and synthesize in the lab. Additionally, aptamers have been chosen for
their several benefits as a new family of cancer therapeutic compared to recent cancer therapies, such as
monoclonal antibodies. These advantages consist of their promising affinity towards specific tumor cell lines,
higher robustness than antibodies, fast in vitro selection, low immunogenicity and better penetration into solid
tumor tissue [14,15]. Because of these unique advantages, scientists extensively have used aptamer-drug
conjugates (ApDCs) with covalent or noncovalent conjugation in targeted cancer therapy [16,17]. Solid-phase

system aids researchers to produce sequence predesigned and automated DNA synthesis from particular
phosphoramidite building blocks (A, T, C, G and D) (Fig. 1) [17].

Fig. 1. Automated and molecular synthesis of ApDCs from phosphoramidite A, T, C, G and D [17]. Repreinted
with permission.
Recently, aptamers have attracted remarkable interest for their competitive advantages compared with other
biological materials [18]. Also, different aptamers have been extensively used to load drugs and nanoparticles
(NPS) for cancer therapy [19]. According to current studies, DNA aptamers were chosen for SK-BR-3 model
breast cancer cell-line. By using the ionic-gelation procedure, NPS-containing DNA aptamers for paclitaxel (PTX)
targeted delivery systems comprising chitosan and Pluronic®F127 (PF) were synthesized [20].
Aptamer-drug-NPS conjugates possess not only a wide range of potential benefits for clinical diagnostics—such
as cancer bacteria, tissues and viruses—but also has outstanding ability in therapeutics [21]. Additionally, these
platforms have succesfully appeared in biosensing. In recent work, Lu et al. performed a one-pot simultaneous
detection of adenosine and cocaine using gold nanoparticles conjugated with aptamers and QDs (quantum
dots). As a result, simultaneous colorimetric and fluorescent detection of mentioned molecules has been
described [22,23]. This review represents the recent advances in aptamer-conjugates development for targeting
breast and prostate cancers from 2008 until now. Also, the complementary discussion of the SELEX system,
nanoparticle-aptamer bioconjugates and SDDS is presented.

2. SELEX technique
Aptamers can be identified through in vitro evolution called SELEX, which makes aptamer identification in a
harmonic process [24]. SELEX is a process or principle for exploring high-affinity oligonucleotide ligand libraries
by the combinational chemistry process [25,26]. In 1990, Tuerk and Gold selected two different RNA sequences
that interact with the T4 DNA polymerase with high affinity and designed the SELEX method for the first time
[27].
SELEX technique is repetitive rounds that allow the identification of unique RNA/DNA molecules from huge
populations of random sequence oligomers that bind to the target, shown in Fig. 2 [28,29]. This process is
performed in four steps:
(1) Selection step for introducing the chemical groups into DNA/RNA library
(2) Bound DNA section (selective to specific target)
(3) Wash to remove unbound DNA
(4) PCR (polymerase chain reaction) amplification

Fig. 2. In vitro selection starts with the generation of a diverse library of DNA or RNA molecules.
Generally, the library of ssDNA is reduced after 5 to 15 cycles to choose only aptamers with high affinity to
targets [30,31]. In this repetitive process, some problems were observed that caused generation of modified
aptamers. In order to fulfill this issue, Click-SELEX protocol has been introduced, which eliminates inappropriate
enzymatic problems [32,33].
Click-SELEX is an attractive idea that allows the introduction of alkyne functional groups. Notably, the chemical
modification of aptamers can be achieved by a combination of click-chemistry with nucleobase and in
vitro selection processes.

3. Recent function of aptamers conjugates for cancer targeting
Design chemotherapy drugs has been really difficult, but this current research may affect the efficiency of
antineoplastic remedy. Today, tumors become insensitive to several drugs in multi-drug resistance (MDR)
[34,35]. Aptamers have been chosen for their several benefits as a new family of cancer therapeutic compared
to recent cancer therapies, such as monoclonal antibodies. These advantages include their promising affinity
towards specific tumor cell lines, higher robustness than antibodies, fast in vitro selection, low immunogenicity
and better penetration into solid tumor tissue [14,15]. The aim of the review in this section is to focus on the
published article over the four years in which aptamers-NPs-drug has been used for cancer targeting. Through
alteration of NIR-absorbing nanocarriers with the ssDNA-caged sgc8 aptamer, Chen et al. demonstrated
magnificent NIR light-activated particular cancer-cell binding with GNRs and SWNTs as a model system. This
strategy has a dual-targeting capability in comparison with recently discovered cancer-targeting processes, such
as reducing non-specific toxicity and increasing selectivity for treating tumor cells [36].
One of the most common drugs to the forefront of cancer therapy is 5-Fu (5-fluorouracil). In the recent study,
Behrooz and his colleagues have developed new aptamer-drug conjugates in order to reduce side effects of 5-Fu
in gastric cancer. They designed a complex consisting of nanocarrier PAMAM (Polyamidoamine), AS1411
aptamer and 5-Fu. The 5-FU-dendrimer- aptamer was capable of effectively delivering chemotherapy drug to
cancer cells, reducing both quantity of cancer cells as well as the IC50 [37]. In a recent study, Martinez and his
colleagues produce the first aptamer to target on tumor cell MRP1-expressing cells with a new combinatorial
SELEX. They developed MRP1-CD28, which can identify the tumor and deliver the CD28 to tumor-infiltrating
lymphocytes. Results have observed a noticeable delay in tumor growth (Fig. 3) [38].

Fig. 3. The overall antitumor effect of the vaccine on mice vaccinated and challenge at day +15 was evaluated by
tumor measurement (5 mice per group) [38]. Reprinted with permission.

4. Breast cancer targeting Aptamer
Breast cancer causes high female mortality, and the number of women who are in jeopardy has increased
recently [39]. Usage of aptamers based on cell-SELEX is increasing for specific recognition of breast cancer cells
[40].
In this section, we highlight some of the important achievements of aptamers, aptasensors and aptamers
conjugated with [1] therapeutic agents [2], nanoparticles and [3] siRNA chimeras based on smart targeted
delivery systems used for the diagnostics and therapeutics of breast cancer targeting in recent years.

4.1. AS1411 breast cancer aptamer

AS1411 is a significant antiproliferative G-rich phosphodiester oligonucleotide used as a remarkable anticancer
agent in Phase II clinical tests [41]. AS1411 has an exceptional structure for binding to a particular cellular
protein and resistance to nuclease degradation [42]. The DNA aptamer AS1411 largely demonstrates a strong
binding affinity to nucleolin (Kd is in pM to low nM range) via its G-quadruplex structure [43]. AS1411 has been
revealed to regulate Rac1 activation and antiproliferative properties that was measured by Bates et al. [44].
Recently, Ghahremani et al. demonstrated a new strategy for effective tumor targeting and megavoltage
radiosensitizing by utilization of AS1411-aptamer conjugates with gold nanoclusters (GNCs) that are synthesized
through BSA as the capping agent (Fig. 4). This method exhibited 39% of radiotherapy efficacy by taking
advantage of flow cytometry and fluorescence microscopy. Importantly, the survival of the mice increased in 9
days [45].

Fig. 4. AS1411 aptamer decorated GNCs for enhancement of radiation therapy effcacy.
Apt–GNCs: Aptamer-conjugated gold Nano-clusters; BSA: Bovine serum albumin [45]. Reprinted with
permission.
In another report, Borghei et al. developed a colorimetric aptasensor based on aggregated nanocarriers in order
to detect breast cancer cells. Fig. 5 illustrates the color change in the presence of the target (breast cancer) cell
and normal cell. Due to the high affinity between the AS1411-aptamer and cancer cell, the removal of aptamers
in the solution was triggered, and therefore, no aptamer remained to hybridize with ssDNA-AuNP, making the
solution red. But, in the absence of breast cancer cell, aptamers assembled ssDNA-AuNP and remained in the
purple solution [46]. Novel nanoparticle-AS1411 aptamer loaded docetaxel in a polydopamine (pD)-based
surface (Apt-pD-DTX/NPs) demonstrated high affinity for both in vivo and in vitro cell studies, as described by
Tao et al. This functionalized Apt-pD-DTX/NPs not only decreased adverse effects of Taxotere but also increased
promising therapy and local drug concentration effects on breast cancer target [10].

Fig. 5. Schematic representation of selective colorimetric method for detection of cancer cells by employing DNA
probe 1,2 -functionalized gold nanoparticles and AS1411 aptamer [46]. Reprinted with permission.

A recent study reported the utilization of AS1411 aptamer conjugated with liposomes (containing DOX
hydrochloride and ammonium bicarbonate) can effectively deliver and accumulate DOX to breast tumor cells
(MCF-7/ADR). In this research, ammonium bicarbonate, a bubble-generating agent, helped to trigger the release
of the DOX quickly into cancer cells simply by local heating (for generating CO2 bubbles), and as a result, the
cancer cells were destroyed (Fig. 6) [47]. In an interesting work in 2017, Zhang and coworkers designed a new
process for targeted drug delivery to MCF-7 breast cancer cells. For this purpose, they offered polymeric
micelles, including poly (ethylene glycol)-poly (β-amino esters) based on doxorubicin and AS1411 aptamer called
PEG-PAEs NPs (PDANs) [48].

Fig. 6. Selective binding of the AS1411 lyposome to nucleolin on breast cell surface, effectively leading to
accumulation of DOX by local heating and generating CO2 bubbles and subsequent receptor-mediated
endocytosis [47]. Reprinted with permission.
Malik et al. constructed a novel AS144-aptamer conjugated to 5 nm gold nanospheres (AS1411-GNS) and
demonstrated their potential applicability in both in vivo and in vitro tests for breast cancer cells. Cells were
incubated with nanospheres for 72 h and proliferation was measured by MTT assay. This conjugated aptamer
exhibited significantly superior cellular uptake and high cytotoxic results. As illustrated in Fig. 7, two important
breast cancer cells, including MCF-7 and MDA-MB-231, as well as non-malignant breast epithetical cells
(MCF10A), were affected by AS1411-GNS. We can see how AS1411-GNS has the antiproliferative effects on MCF7 and MDA-MB-231, but not major inhibitory impact on MCF10A. High selectivity, improved growth inhibitory
and increased cytotoxicity are other advantages of this research, which make them prospective candidates for
clinical translation [49].

Fig. 7. Antiproliferative activity of AS1411-GNS on the growth of breast cancer cells toward MCF-7, MDA-MB-231
and MCF10A in different concentrations [49]. Reprinted with permission.

4.2. EpCAM breast cancer aptamer

Epithelial cell adhesion molecule (EpCAM also known as CD326 or ESA), a cell surface glycoprotein of
approximately 40 kDa, is overexpressed in a variety of epithelial cancer cell lines such as breast, colon and
ovarian cancer. Epithelial cell adhesion molecule is a well-known antigen that plays an important role human
colon carcinoma tissue [50]. This molecule has gained enormous interest for novel cancer targeting, especially

for breast cancer cell surface [51] and efficiently applied in the case of developing new therapeutic approaches
for targeted drug delivery [52].
To date, scientists have made several attempts to utilize more EpCAM-aptamer as a good way for cancer
diagnosis and therapy, particularly for breast cancer. In this regard, Hadizadeh et al. developed an EpCAMaptamer conjugated with PEG–PLGA copolymer for delivering doxorubicin (DOX) into a breast cancer cell in
vitro. Fig. 8 demonstrates the procedure for synthesizing of doxorubicin-loaded aptamer conjugated
nanopolymersomes, which were more cytotoxic (P < 0.01) toward MCF-7 than non-targeted
nanopolymersomes. The results of this research were admirable due to the increasing the DOX release rate up
to 8% over 5 days [53].

Fig. 8. Process of producing EpCAM-aptamer conjugated DOX-loaded nanopolymersomes.
In continuation, Shigdar et al. developed 19-nt RNA aptamer, which was isolated from 40-base RNA aptamer
that binds selectively to EpCAM in the breast, colorectal and gastric cancers, followed by active internalization,
for the first time. They evaluated the binding affinity of the EpCAM RNA aptamer to a specific target through
flow cytometry and confocal microscopy and the affinity was approximately 55 nM. Importantly, this EpCAM
RNA aptamer is efficiently internalized after binding to cell surface EpCAM [54]. In another report in 2017, Xiang
and his group developed a novel EpCAM aptamer to tackle the problems with chemotherapy-resistant cancer
stem cells and enhance the doxorubicin intercalation to colorectal, ovarian and breast cancer [55]. In an
interesting effort, to address the Dox-resistance and deliver efficacy of the Dox to in vivo MCF-7 human breast
cancer cells, a new strategy was reported by Wang et al. For this purpose, they used EpCAM aptamer-siRNA and
Dicer Survivin, an important protein in drug resistance, which is highly expressed in cancer stem. As a result, this
strategy demonstrated a high dose of the siRNA delivered to MCF-7 cell in xenograft tumors and silencing of
survivin with EpCAM aptamer-siRNA chimera in cancer stem cell population [56].
Locked Nucleic Acid (LNA) modification is responsible for demonstrating increased hybridization affinity toward
complementary of RNA and DNA [57], which was first synthesized by Wengel et al. [58]. The potential in
vivo roles of LNA-modified EpCAM-aptamer was performed toward an experiment with the MDAMB453 breast
cancer cells siRNA transfection as a positive control. Consequently, MDAMB453 was inhibited remarkably and
showed high fluorescence intensity (MFI) [59].

4.3. MUC1 as a breast cancer aptamer

MUC1 is one of the important breast cancer targets that is overexpressed at the apical surface in various types
of reproductive tract epithelia including lung, kidney, stomach, pancreas and breast [60]. It is also an effective
tumor-associated antigen (TAA). Dai and his colleagues reported a valuable targeted delivery system for
delivering DOX to breast cancer cells in vitro. In this project, MUC1 positive target was bound to DNA
tetrahedron to make apt-td, which could deliver DOX to MUC1-positive breast cancer cells with high affinity, but

not to negative breast cancer targets. Compared to free MUC1-aptemer (one per aptamer), this material has a
high capacity to load the DOX (25 per apt-td) [61]. In another work, based on the smart drug delivery
approaches that aid scientists to develop cytotoxic drugs with reduced dosage, the novel 86-base DNA aptamer
(MA3) was designed to selectively deliver the cytotoxic DOX only to the MUC1-positive breast cancer cells.
However, an in vivo study is essential to assess the stability of MA3-apt in blood and tissue [62]. Mesoporous
silica nanoparticles (MSNs) have attracted great attention as multifunctional smart nanocarriers for drug
delivery system and cell imaging [63]. Following this approach, Hanafi-Bojd et al. designed a MUC1-aptamer
conjugated MSNs in order to deliver Epirubicin (EPI) effectively to breast cancer cells. They demonstrated that
MSN-MUC1-EPI has been a significant improvement in cytotoxicity versus MSN-EPI against MCF-7 cells [64]. In
order to specifically release drugs in tumoral cells, MSNs loaded with safranin O conjugated MUC1 aptamer (S1apMUC1) was developed by Pascual et al. The same procedure was used to load DOX instead of safranin O (S2apMUC1). Both compounds were internalized significantly by MUC1 overexpressed breast cancer cells and
delivered remarkable cargo (safranin O and DOX) to cancer cell line. S1-apMUC1-Tc (S1-apMUC1 with 99mTc
radioisotope) was used as a radiolabeling tool (Fig. 9) [65].

Fig. 9. (A) Schematic diagram for synthesis of S1-apMUC1, S2-apMUC1 and S1-apMUC1-Tc. (B) The role of S1apMUC1-Tc [65]. Reprinted with permission.
Yu et al. exploited MUC1-aptamer for increasing drug delivery and cytotoxicity (P < 0.01) in comparison with
paclitaxel to MCF-7 cancer cells loaded by liposomal formulations [8]. Also, Jo et al. developed a dual-aptamer
modified silica nanoparticles (dye-doped) system with high affinity to both mucin 1 (MUC-1) (+) and epidermal
growth factor receptor 2 (HER-2) (+) breast cancer cells. In comparison with the single aptamer, the mentioned
system showed high selectivity and promising detection of breast cancer, as well as low cytotoxicity [66].

4.4. HER2 as a breast cancer aptamer

The human epidermal growth factor receptor 2 (HER2 or ErbB2) consists of HER1, HER3 and HER4 [67] and was
discovered in 1985. HER2 overexpression plays an important role in different types of human malignancies [68].
HER2 is one of the important targets that has been examined in breast cancer therapy [69]. Having HER2
positive breast cancer in human increases mortality and causes high recurrence rates [70]. Determination of
HER2 positive has been considered as an important method in cancer diagnosis [71]. Sett et al. made a point of
developing a novel DNA aptamer against the extracellular domain (ECD apt1) of HER2. In this study, based on in
vitro SELEX process, ECD apt1 demonstrated cytoplasmic staining in overexpression HER2 [72]. Likewise,

conjugation of ECD apt1 with biotin exhibited powerful cytoplasmic staining in SKBR3 than MDA-MB-231 and
MCF-7 [73]. Nguyen et al. reported HER2 aptamer-micelle for delivering better of PTX and effective detection of
human HER2 overexpressing SK-BR-3 breast cancer cell lines. The designed PTX-chitosan grafted to pluronic
F127 copolymer micelles with DNA aptamer. The results showed a higher affinity and cytotoxicity of the
designed platform in comparison with PTX and bare ap-micelles [74]. Recently, Yu et al. developed three-in-one
aptamer-siRNA chimera that targeted EGFR/HER2/HER3 in one molecule, both in vitro and in vivo. They created
a HER2 aptamer-EGFR siRNA-HER3 (H2EH3), shown in Fig. 10. H2EH3 exhibited high affinity and selectivity to
breast cancer xenograft models, compared to both HER2 aptamer and HER3 aptamer. In addition, tumor growth
was inhibited dramatically [75].

Fig. 10. Structure of H2EH3, which constitutes from conjugation of HER2 aptamer with HER3 aptamer through 21
bases of EGFR siRNA and 2–4 unpaired base linkers [75]. Reprinted with permission.
In 2018, Shen et al. developed pH-responsive micelle-like nanoparticles (MNPs) based-HER2 aptamer (HAptMNPs). Compared to free HER2 aptamer, the HApt-MNPs was able to Ref. [1] deliver more effectively to a
specific target and [2] enhance HER2 aptamer uptake and lysosomal transport in HER2 SKBR3 cells in vitro (Fig.
11) [76].

Fig. 11. sKBr3 cells were treated with hapt-MNPs or free hapt for 8 h at the same hapt concentration (125 nM),
followed by fresh complete media for 16 h, then stained with lysosome tracker (green fluorescence) and
Hoechst 33342 (blue fluorescence). (A) Confocal fluorescence microscopy images. Cellular signals were much
stronger for hapt-MNPs (red, top panel) than free-hapt (red, bottom panel). scale bars = 10 μm. (B) Western blot
of her2 protein expression. β-actin was used as a protein loading control. Mean (±sD) her2 band intensity was

24,454.43 (±1632.02) for hapt-MNPs and 79,276.08 (±2162.13) for free hapt (n = 3) [76]. Reprinted with
permission.

4.5. The other nanocarriers-aptamer bioconjugates for breast cancer treatment

Since gold nanoparticle (AuNP) has a wide variety of applications on account of their color transition properties,
aptamer-functionalized AuNP was developed for detecting the human estrogen receptor alpha (ERα), a crucial
biomarker in breast cancer diagnosis, by Ahirwar and coworkers. This colorimetric aptasensor was tested on
cellular extracts from MCF-7 and MDA-MB-231 breast cancer cells and subsequently changing the color of
aptamer-protected nanoparticles became visible from red to the blue of aggregated AuNPs [77]. Notably, in
vitro conjugation of aptamer 1(Apt1) and PEGylated liposomes demonstrated a high affinity to CD44 + cancer
cells line compared with CD44− 3T3 [78].

5. Prostate cancer targeting Aptamer

Prostate cancer (PC) is the second most common cancer among the men in the world [79] after lung cancer
[80]. Current studies in prostate cancer demonstrate that localized prostate cancer can be cured significantly, do
not have remarkable survival benefits and many men die annually for metastatic prostate disease [81,82].
Inhibiting the androgen receptor (AR), the main oncogenic driver in prostate cancer, is the ongoing projects that
many drugs are attempting to achieve [83]. In this part, we demonstrate the most important studies of
aptamers and aptamers conjugated with therapeutic agents and nanoparticles, based on smart targeted delivery
system that have been used for diagnostics and therapeutics of prostate cancer targeting in recent years.

5.1. Prostate specific membrane antigen aptamer

Prostate-specific membrane antigen (PSMA, also known as A10) is the most famous cell surface antigen of
prostate cancer that is highly expressed on the surface of human prostatic adenocarcinoma (LNCaP)
[[84], [85], [86]]. It is assessed in primary and metastatic prostate tumor cells, which have been an important
target for prostate cancer diagnosis and therapeutic [87]. Leach et al. synthesized a new RNA and DNA hybrid
aptamer named A10-3-J1 based on A10-3 aptamer with high affinity to PSMA. In this study, A10-3-J1 is
selectively conjugated with superparamagnetic iron oxide nanoparticles (SPIO-NP) in order to load DOX to
PSMA+ prostate cancer cells. This experiment brought some significant results, such as enhancing the
cytotoxicity of targeted cells, mitigating collateral damage and increasing affinity of DOX [88]. Several studies
have described gold nanoparticles as great candidates for prostate cancer treatment due to their positive effects
on prostate cancer cell lines [89]. In this regard, Kim and coworkers developed a multifunctional gold
nanoparticles conjugated with PSMA-specific A9 RNA aptamer for selective delivery of DOX to overexpressed
PSMA of prostate cancer cells that enables combined prostate cancer imaging by computed tomography (CT).
They demonstrated the effective capability of this aptamer for killing target prostate cancer cell more than nontarget cells [90]. Efficient delivery of microRNA (miR-15a and miR-16-1) to in vivo and in vitro PSMA target was
performed by Hao and his group. They used A10–3.2 aptamer (APT) conjugated with Atelocollagen (ATE), ATEAPT, which were loaded with miR-15a and miR-16-1 to PC3 (PSMA−) and LNCaP (PSMA+) targets. In
vivo anticancer activity was investigated using the survival times of human PCa bone metastasis mice model.
ATE-APT was able to deliver miR-15a and miR-16-1 to PSMA cells and, consequently, could kill the PCa cells in
bone metastatic foci and improve cell viability (Fig. 12) [91].

Fig. 12. Viability of LNCaP cells treated with miRNA/ATE–APT, NC-miRNA/ATE–APT and miRNA/ATE complexes
(n = 3, error bars represent the standard deviation). APT, aptamer; ATE, atelocollagen; and NC, negative control
[91]. Reprinted with permission.
Zhang et al. reported synthesis of a DNA nanoparticle containing PSMA-aptamer for targeted drug delivery of
DOX using a pH-sensitive spacer composed of adenine repeats. Because of integration of pH-sensitive spacer,
nanoparticles were able to break apart at acidic pH, and therefore caused fast release of the DOX. Moreover, a
cell uptake study showed that DOX was bound to more PSMA+ cells than PSMA-null cells for prostate cancer
therapy [92,93]. Farokhzad et al. utilized docetaxel (DTX) encapsulated with PLG-PEG copolymer, which
functioned with A10 2-fluoropyrimidine RNA aptamer (DTX-NP-Apt) that binds effectively to PSMA on the
surface of LNCaP prostate cancer cell. In vitro (P < 0.0004) and in vivo cellular toxicity increased remarkably using
a LNCaP xenograft nude mouse model of PCa that results in enhanced cytotoxicity and anticancer activity
[94,95]. Antitumor activity of aptamer nanoparticle for acceptable loading of DTX (DTX-apt-NPs) was performed
against both in vivo and in vitro prostate cancer. Sodium oleate and PLG-b-PEG were utilized through the solvent
diffusion procedure. Gao et al. reported that DTX-apt-NPs could dramatically improve the delivery of DTX to
PSMA+ prostate cancer and increased the antitumor efficacy of DTX by aptamer-mediated intracellular delivery
(Fig. 13) [96].

Fig. 13. Effective delivery of DTX through DTX-apt-NPs [96]. Reprinted with permission.

Cisplatin demonstrated high ability in a clinical trial to manage metastatic castration-resistance prostate cancer,
however, its resistance and adverse effects make it a drug with limited use in cancer therapy [97,98]. In order to
tackle these problems, Dhar and his group developed an applicable strategy by using Pt (IV)-encapsulated PSMAaptamer of PLG-b-PEG nanoparticles. As a result, suitable dose of Cisplatin was loaded to target PSMA. Also,
effective targeting against PSMA+ LNCaP was described [99]. In addition, the combination of ApDCs with
radiotherapy in PSMA+ tumor and their noticeable therapeutic results has been described [100]. In vitro study
evaluated the potential of targeted liposomes loaded with 225Ac. In this study, A10 anti-PSMA-aptamer
conjugated with PEGylated liposomes loaded with a-particle generator 225Ac selectively killed prostate-specific
membrane antigen. The results of this report confirmed the rapid internalizing, selective binding to specific
target and PSMA+ killing [101].

6. Conclusion and future prospects
Breast and prostate cancers' mortality as the most important types of cancers have taken a heavy toll on women
and men, respectively; hence there is a growing need for assessing diagnosis and treatment. Several attempts
have been made to address these cancers such as chemotherapy and radiation which most of them bring about
several problems including low accumulation in tumor cells and low target selectivity. Therefore, targeted drug
delivery may tackle these limitations and improve their disadvantages. In recent years, aptamers and synthetic
oligonucleotide moleclules isolated in vitro demonstrated high target affinity as well as reduced toxicity.
Aptamer-bioconjugates with a wide variety of benefits have demonstrated multifunctional capability for breast
and prostate therapies and diagnostics. Nevertheless, remarkable challenges and issues remain to be tackled to
use them for clinical use, such as low drug loading, weakly understood pharmacokinetics, toxicity and costly in
vivo testing. More imporatantly, due to the small size and the rapid degradability of aptamers through different
nucleases in vivo, they are more likely to be modified by different groups of agents resulted in increased cost
and side effects. To solve this, scientists should carry out more animal models for the evaluation of safety and
efficacy of aptamer-bioconjugates. Moreover, as finding potential targets needs boundless time and effort, the
SELEX technology is quite time consuming and labor intensive even though a variety of methods are being
developed for aptamer screening. Thus, different methods should be taken into consideration to decrease the
cost of aptamer SELEX strategy in vivo in the future. In this sense, in order to reduce toxicity and improve target
efficacy of aptamer-bioconjugates, some procedures can be investigated carefully such as surface charge,
coating, biocompatibility and biodegradability of conjugates as well as optimization of the surface modification
of conjugates. To the best of our knowledge, although aptamer-bioconjugates play an indispensable role in
cancer therapy, to accurately assess therapeutic efficacy and ameliorate clinical practise of aptamerbioconjugates, it is of paramount importance to evaluate more clinically and pathologically in relation to animal
models. Furthermore, the SELEX strategy requires more experiments to choose appropriate aptamers from an
oligonucleotide library. For the near future, we should be hopeful for the design of new generations of
nanocarriers-aptamer bioconjugates to address all limitations, particularly, for clinical use. Some of the aptamerdrug conjugates systems are summarized in Table 1.

Table 1. Some other aptamer-drug conjugate systems for targeted drug delivery.
Target
PSMA(PC)
PSMA(PC)
PSMA(PC)
PSMA(PC) nanobubbles

Aptamer(DNA/
RNA)
E3
A10
A10–3.2
A10–3.2

Therapeutic agent

Status

Ref

MMAE and MMAF
Plumbagin
Paclitaxel
siRNA-cationic

In vivo and In vitro
In vivo
In vivo and In vitro
In vivo and In vitro

[102]
[103]
[104]
[105]

PSMA(PC)
MUC1(BC)
MUC1(BC)
MUC1(BC)
Nucleolin FOXM1(BC)
Nucleolin
Nucleolin
Nucleolin
Nucleolin
Nucleolin
HER2+(BC)
HER2+(BC)
HER2+(BC)
EpCAM(BC)
EpCAM(BC)

A10
DNA aptamer
DNA aptamer
DNA aptamer
AS1411 and
AS1411(BC)
AS1411(BC)
AS1411(BC)
AS1411(BC)
AS1411(BC)
HER2
A6
HB5
EpCAM
EpCAM

TFO
Doxorubicin
Paclitaxel
miR-34a
Doxorubicin
Doxorubicin
Paclitaxel
Cisplatin
Doxorubicin
Fluorescein
Docetaxel
P-gp
Doxorubicin
Nutlin-3a
Neocarzinostatin

In vivo
In vivo and In vitro
In vitro
In vivo and In vitro
In vivo and In vitro
In vivo and In vitro
In vitro
In vitro
In vivo and In vitro
In vivo and In vitro
In vivo and In vitro
In vitro
In vitro
In vitro
In vitro

[106]
[107]
[108]
[109]
[110]
[111]
[112]
[113]
[18]
[114]
[115]
[116]
[117]
[118]
[119]

PSMA: Prostate-specific membrane antigen, MMAE: Monomethyl auristatin E, MMAF: Monomethyl auristatin F,
TFO: Triplex forming oligonucleotides, HER2: Human epidermal growth factor receptor 2, EpCAM: Epithelial cell
adhesion molecule.
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